A phase 3, randomized, double-blind trial of nivolumab or nivolumab plus ipilimumab versus placebo in patients with localized renal cell carcinoma who underwent radical or partial nephrectomy and are at high risk of relapse (CheckMate 914)
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI